» Articles » PMID: 27199481

MerTK Cleavage Limits Proresolving Mediator Biosynthesis and Exacerbates Tissue Inflammation

Overview
Specialty Science
Date 2016 May 21
PMID 27199481
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

The acute inflammatory response requires a coordinated resolution program to prevent excessive inflammation, repair collateral damage, and restore tissue homeostasis, and failure of this response contributes to the pathology of numerous chronic inflammatory diseases. Resolution is mediated in part by long-chain fatty acid-derived lipid mediators called specialized proresolving mediators (SPMs). However, how SPMs are regulated during the inflammatory response, and how this process goes awry in inflammatory diseases, are poorly understood. We now show that signaling through the Mer proto-oncogene tyrosine kinase (MerTK) receptor in cultured macrophages and in sterile inflammation in vivo promotes SPM biosynthesis by a mechanism involving an increase in the cytoplasmic:nuclear ratio of a key SPM biosynthetic enzyme, 5-lipoxygenase. This action of MerTK is linked to the resolution of sterile peritonitis and, after ischemia-reperfusion (I/R) injury, to increased circulating SPMs and decreased remote organ inflammation. MerTK is susceptible to ADAM metallopeptidase domain 17 (ADAM17)-mediated cell-surface cleavage under inflammatory conditions, but the functional significance is not known. We show here that SPM biosynthesis is increased and inflammation resolution is improved in a new mouse model in which endogenous MerTK was replaced with a genetically engineered variant that is cleavage-resistant (Mertk(CR)). Mertk(CR) mice also have increased circulating levels of SPMs and less lung injury after I/R. Thus, MerTK cleavage during inflammation limits SPM biosynthesis and the resolution response. These findings contribute to our understanding of how SPM synthesis is regulated during the inflammatory response and suggest new therapeutic avenues to boost resolution in settings where defective resolution promotes disease progression.

Citing Articles

Early-age efferocytosis directs macrophage arachidonic acid metabolism for tissue regeneration.

Lantz C, Becker A, DeBerge M, Filipp M, Glinton K, Ananthakrishnan A Immunity. 2025; 58(2):344-361.e7.

PMID: 39938482 PMC: 11839170. DOI: 10.1016/j.immuni.2024.11.018.


Oxidative Stress and Energetic Failure: Common Features and Dissimilarities in 3 Different Mouse Models of Retinal Pigment Epithelium Phagocytosis Defects.

Vanoni E, Enderlin J, Rieu Q, Hamieh F, Rety S, Nandrot E Adv Exp Med Biol. 2025; 1468:259-263.

PMID: 39930206 DOI: 10.1007/978-3-031-76550-6_43.


Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy.

Bu S, Ling J, Wu X, Zhang L, Shi X, Huang L Front Endocrinol (Lausanne). 2025; 15():1509445.

PMID: 39845889 PMC: 11750652. DOI: 10.3389/fendo.2024.1509445.


Chitinase-3-like Protein 1 Reduces the Stability of Atherosclerotic Plaque via Impairing Macrophagic Efferocytosis.

Liu Y, Hu W, Yang F, Zou S, Ren H, Zuo Y J Cardiovasc Transl Res. 2025; 18(1):3-16.

PMID: 39813006 DOI: 10.1007/s12265-024-10576-w.


Functions of TAM Receptors and Ligands Protein S and Gas6 in Atherosclerosis and Cardiovascular Disease.

Prouse T, Majumder S, Majumder R Int J Mol Sci. 2024; 25(23).

PMID: 39684449 PMC: 11641688. DOI: 10.3390/ijms252312736.


References
1.
Cohen P, Caricchio R, Abraham V, Camenisch T, Jennette J, Roubey R . Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med. 2002; 196(1):135-40. PMC: 2194017. DOI: 10.1084/jem.20012094. View

2.
Scott R, McMahon E, Pop S, Reap E, Caricchio R, Cohen P . Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001; 411(6834):207-11. DOI: 10.1038/35075603. View

3.
Arnardottir H, Dalli J, Colas R, Shinohara M, Serhan C . Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol. 2014; 193(8):4235-44. PMC: 4185223. DOI: 10.4049/jimmunol.1401313. View

4.
Lee Y, Han J, Byun J, Park H, Park E, Chong Y . Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1/3, and NF-κB activation and enhances inflammatory responses in lipopolysaccharide-induced acute lung injury. J Leukoc Biol. 2012; 91(6):921-32. DOI: 10.1189/jlb.0611289. View

5.
Zagorska A, Traves P, Lew E, Dransfield I, Lemke G . Diversification of TAM receptor tyrosine kinase function. Nat Immunol. 2014; 15(10):920-8. PMC: 4169336. DOI: 10.1038/ni.2986. View